Venker Eric 4

What Happened

• Eric Venker, President of Roivant Sciences (and CEO of Immunovant), exercised stock options and sold the resulting shares on March 17, 2026. The filing shows an exercise (M) of 200,000 shares at $3.85 per share (cost = $770,000) and an open-market sale (S) of 200,000 shares at a weighted average price of $28.24 per share (gross proceeds ≈ $5,648,000). The same Form 4 also lists a derivative conversion line for 200,000 shares reported as disposed at $0; the filing does not provide further explanation for that line.

Key Details

• Transaction date: March 17, 2026.
• Exercise: 200,000 shares at $3.85 per share (total exercise cost $770,000).
• Sale: 200,000 shares sold at a weighted average price of $28.24 (range $28.04–$28.45); total proceeds ≈ $5,648,000. (Footnote F1: sale price is weighted average; posting lists range and offers to provide per-price breakdown on request.)
• Options background: Footnote F2 indicates these were options from an award with a vesting commencement date of April 20, 2022 (25% at the first anniversary, then monthly vesting over 36 months).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Report filed March 19, 2026 for a March 17 transaction; appears to be within the Form 4 reporting window (timely).

Context

• This appears to be an exercise of vested options followed by an immediate open-market sale of the resulting shares (commonly done to realize gains or cover exercise costs). The filing is factual and does not state Venker’s motivations. For more detail (e.g., exact number of shares sold at each price within the reported range or explanation of the $0 derivative line), the filing’s footnotes indicate the reporter will provide that information upon request or you can view the full Form 4 on the SEC EDGAR system.